Johnson & Johnson (NYSE: JNJ) has officially closed out what CEO Joaquin Duato described as a “catapult year,” reporting robust financial results for the fourth quarter and full-year 2025. Driven by a surge in oncology sales and strategic acquisitions, the healthcare giant is now positioning itself to exceed $100 billion in annual revenue for the first time in 2026.
Financial Highlights: A Year of Accelerated Growth
For the full year 2025, Johnson & Johnson reported total sales of $94.2 billion, a 6.0% increase over 2024. The company’s net earnings saw a dramatic surge, nearly doubling to $26.8 billion, while reported earnings per share (EPS) reached $11.03.
Q4 2025 Performance:
- Reported Sales: $24.6 billion (up 9.1% YoY).
- Adjusted EPS: $2.46 (up 20.6% YoY), which includes a $0.10 impact from the acquisition of Halda Therapeutics.
- Net Earnings: $5.1 billion, representing a 49.1% increase compared to Q4 2024.
Segment Performance
Innovative Medicine (formerly Janssen)
The segment delivered $15.76 billion in Q4 sales, a 10% reported increase. Growth was heavily supported by its oncology portfolio:
- Oncology Drivers: Blockbuster drugs DARZALEX and CARVYKTI continued to see strong adoption.
- Immunology: Growth in TREMFYA helped offset a significant decline in STELARA sales, which faced a 1,040 basis point headwind due to biosimilar competition and pricing pressures.
- Neuroscience: SPRAVATO and the newly approved CAPLYTA (for major depressive disorder) contributed to a 19.1% operational growth in this sub-segment.
MedTech
The MedTech division reported $8.8 billion in Q4 sales, up 7.5%.
- Strategic Focus: The company is aggressively shifting its MedTech portfolio toward higher-growth areas like cardiovascular, surgery, and vision.
- Innovation: A major milestone was the submission of the OTTAVA Robotic Surgical System to the FDA, signaling J&J’s intent to compete more directly in the digital surgery space.
Read More: Johnson & Johnson Raises 2025 Sales Outlook on Strong Q3 Performance
Strategic Transformation: The DePuy Synthes Spinoff
In a move to further streamline operations, Johnson & Johnson confirmed its intent to separate its Orthopaedics business (DePuy Synthes) into a standalone company. This separation, expected to take 18–24 months, will allow the core J&J business to focus on high-margin innovative medicines and advanced MedTech sectors like robotics. Namal Nawana has been appointed to lead DePuy Synthes through this transition.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
2026 Outlook: The $100 Billion Goal
Looking ahead, Johnson & Johnson issued optimistic guidance for 2026, forecasting reported sales between $100.0 billion and $101.0 billion.
- 2026 Sales Midpoint: $100.5 billion (6.7% growth).
- 2026 Adjusted EPS Midpoint: $11.53 (6.9% growth).
Market Reaction
Despite the record revenue and strong guidance, J&J shares saw a slight pre-market dip of approximately 2%, as investors weighed the $0.07 miss on adjusted EPS consensus estimates (impacted by acquisition costs) and the ongoing transition of the STELARA franchise. However, analysts remain generally positive on the company’s long-term roadmap and aggressive pipeline expansion.
Last Modified:
